279 related articles for article (PubMed ID: 33537861)
1. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
More LA; Lane S; Asnani A
Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861
[TBL] [Abstract][Full Text] [Related]
2. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
[TBL] [Abstract][Full Text] [Related]
3. Fluoropyrimidine-Associated Cardiotoxicity.
Kanduri J; More LA; Godishala A; Asnani A
Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
[TBL] [Abstract][Full Text] [Related]
4. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
5. Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity.
Saif MW
Onco Targets Ther; 2020; 13():10197-10206. PubMed ID: 33116601
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.
Raber I; Warack S; Kanduri J; Pribish A; Godishala A; Abovich A; Orbite A; Dommaraju S; Frazer M; Peters ML; Asnani A
Oncologist; 2020 Mar; 25(3):e606-e609. PubMed ID: 32162823
[TBL] [Abstract][Full Text] [Related]
7. 5-fluorouracil and cardiotoxicity: a review.
Sara JD; Kaur J; Khodadadi R; Rehman M; Lobo R; Chakrabarti S; Herrmann J; Lerman A; Grothey A
Ther Adv Med Oncol; 2018; 10():1758835918780140. PubMed ID: 29977352
[TBL] [Abstract][Full Text] [Related]
8. Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME; Wickramasinghe CD; Peralta MV; Yang EH
Curr Oncol Rep; 2016 Jun; 18(6):35. PubMed ID: 27113369
[TBL] [Abstract][Full Text] [Related]
9. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
10. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
11. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
13. Fluoropyrimidine-induced cardiotoxicity.
Depetris I; Marino D; Bonzano A; Cagnazzo C; Filippi R; Aglietta M; Leone F
Crit Rev Oncol Hematol; 2018 Apr; 124():1-10. PubMed ID: 29548480
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
15. Two patients with fluoropyrimidine overdose successfully managed without uridine triacetate.
Kats CJ; Jochems A; Jeurissen FJ; Ledeboer A; van den Berg RB
J Oncol Pharm Pract; 2023 Dec; 29(8):2037-2040. PubMed ID: 37499216
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil-related Cardiotoxicity with Coronary Vasospasms.
Faheem B; Kania B; Ashkar H; Bondili L; Maroules M
J Community Hosp Intern Med Perspect; 2022; 12(5):71-74. PubMed ID: 36262502
[TBL] [Abstract][Full Text] [Related]
17. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
18. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Garcia RAG; Saydoff JA; Bamat MK; von Borstel RW
Toxicol Appl Pharmacol; 2018 Aug; 353():67-73. PubMed ID: 29908244
[TBL] [Abstract][Full Text] [Related]
19. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate.
Santos C; Morgan BW; Geller RJ
Am J Emerg Med; 2017 May; 35(5):802.e7-802.e8. PubMed ID: 27884585
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
